Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis

Código QR

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis

This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huo Geng-wei, Zuo Ran, Song Ying, Chen Wei-dong, Chen Wen-ming, Chong Dao-qun, Zhang Hong-mei, Jia Sha-sha, Chen Peng
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	non-small cell lung cancer nivolumab antibiotics survival meta-analysis Medicine R
Acceso en línea:	https://doaj.org/article/59ee09264e6d483cb51ffc33423a2a66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
por: Ammar Haikal, et al.
Publicado: (2018)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
por: Koji Nakajima, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
por: Wen Dong, et al.
Publicado: (2021)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Xiaozhun Huang, et al.
Publicado: (2021)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Toshiki Ogiwara, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Koji Iinuma, et al.
Publicado: (2021)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Morten Fink, et al.
Publicado: (2021)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
por: Keisuke Minami, et al.
Publicado: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Hiroto Yoneda, et al.
Publicado: (2021)

IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
por: Taylor A. Harper, et al.
Publicado: (2021)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
por: Tsuchiya-Kawano Y, et al.
Publicado: (2021)

Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
por: Alejandro David Bendala Estrada, et al.
Publicado: (2021)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Xiaochen Chen, et al.
Publicado: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Comparison of single- and triple-port VATS for lung cancer: A meta-analysis
por: Gao Yunfei, et al.
Publicado: (2021)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
por: Fabio Guolo, et al.
Publicado: (2021)

Carcinoma bronquioloalveolar, ¿Diagnóstico precoz?: Experiencia 1994-1997 en el Instituto Nacional del Tórax
por: GUACHALLA U.,JAIME, et al.
Publicado: (2002)

Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021)

Prognostic Difference of Pleural versus Distant Metastasis after Surgery for Lung Cancer
por: Kyla D. Joubert, et al.
Publicado: (2021)

The composition of lung microbiome in lung cancer: a systematic review and meta-analysis
por: Sadaf Najafi, et al.
Publicado: (2021)

Evaluation of the Therapeutic Outcomes of Antibiotic Regimen Against Carbapenemase-Producing Klebsiella pneumoniae: A Systematic Review and Meta-Analysis
por: Clement Yaw Effah, et al.
Publicado: (2021)

Neutropenic Fever in Lung Cancer: Clinical Aspects Related to Mortality and Antibiotic Failure
por: Inês RODRIGUES, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Artificial Intelligence and Antibiotic Discovery
por: Liliana David, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Ziyu Wang, et al.
Publicado: (2021)

Antibiotics: Combatting Tolerance To Stop Resistance
por: Etthel M. Windels, et al.
Publicado: (2019)

Treatment of advanced small cell lung cancer. Clinical case and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

ANTIBIOTIC RESISTANCE: PUBLIC KNOWLEDGE AND PERCEPTION OF ANTIBIOTIC USE IN RELATION TO SOCIAL DETERMINANTS
por: Hina ` Shan, et al.
Publicado: (2019)

Epidemiology of lung cancer
por: Krishna Chaitanya Thandra, et al.
Publicado: (2021)

Short term and Long term Survival Rate and Risk Factors of Graft Rejection after Deceased Donor Kidney Transplantation: A Systematic Review and Meta-Analysis
por: Behzad Narouie, et al.
Publicado: (2021)

miR-21-5p is a Biomarker for Predicting Prognosis of Lung Adenocarcinoma by Regulating PIK3R1 Expression
por: Du J, et al.
Publicado: (2021)

Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
por: Wu ZL, et al.
Publicado: (2020)